Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection

Victor A. Garcia-Angulo, Anjana Kalita, Alfredo Torres

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective clinical treatment, sequelae after infection and mortality rate in humans supports the urgent need of prophylactic approaches, such as development of vaccines. Shedding from cattle, the main EHEC reservoir and considered the principal food contamination source, has prompted the development of licensed vaccines that reduce EHEC colonization in ruminants. Although murine models do not fully recapitulate human infection, they are commonly used to evaluate EHEC vaccines and the immune/protective responses elicited in the host. Mice susceptibility differs depending of the EHEC inoculums; displaying different mortality rates and Stx-mediated renal damage. Therefore, several experimental protocols have being pursued in this model to develop EHEC-specific vaccines. Recent candidate vaccines evaluated include those composed of virulence factors alone or as fused-subunits, DNA-based, attenuated bacteria and bacterial ghosts. In this review, we summarize progress in the design and testing of EHEC vaccines and the use of different strategies for the evaluation of novel EHEC vaccines in the murine model.

Original languageEnglish (US)
Pages (from-to)3229-3235
Number of pages7
JournalVaccine
Volume31
Issue number32
DOIs
StatePublished - 2013

Fingerprint

Escherichia coli Vaccines
Enterohemorrhagic Escherichia coli
enterohemorrhagic Escherichia coli
animal models
vaccines
Infection
infection
Shiga Toxins
verotoxins
Vaccines
vaccine development
Food Contamination
hemolytic uremic syndrome
Hemolytic-Uremic Syndrome
Mortality
complications (disease)
Large Intestine
colitis
Ruminants
food contamination

Keywords

  • Bacterial ghost
  • Diarrhea
  • EHEC
  • Enterohemorrhagic E. coli
  • Murine model
  • Shiga toxin
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection. / Garcia-Angulo, Victor A.; Kalita, Anjana; Torres, Alfredo.

In: Vaccine, Vol. 31, No. 32, 2013, p. 3229-3235.

Research output: Contribution to journalArticle

Garcia-Angulo, Victor A. ; Kalita, Anjana ; Torres, Alfredo. / Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection. In: Vaccine. 2013 ; Vol. 31, No. 32. pp. 3229-3235.
@article{f87626fe8d904d85b489660e73d1a16b,
title = "Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection",
abstract = "Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective clinical treatment, sequelae after infection and mortality rate in humans supports the urgent need of prophylactic approaches, such as development of vaccines. Shedding from cattle, the main EHEC reservoir and considered the principal food contamination source, has prompted the development of licensed vaccines that reduce EHEC colonization in ruminants. Although murine models do not fully recapitulate human infection, they are commonly used to evaluate EHEC vaccines and the immune/protective responses elicited in the host. Mice susceptibility differs depending of the EHEC inoculums; displaying different mortality rates and Stx-mediated renal damage. Therefore, several experimental protocols have being pursued in this model to develop EHEC-specific vaccines. Recent candidate vaccines evaluated include those composed of virulence factors alone or as fused-subunits, DNA-based, attenuated bacteria and bacterial ghosts. In this review, we summarize progress in the design and testing of EHEC vaccines and the use of different strategies for the evaluation of novel EHEC vaccines in the murine model.",
keywords = "Bacterial ghost, Diarrhea, EHEC, Enterohemorrhagic E. coli, Murine model, Shiga toxin, Vaccine",
author = "Garcia-Angulo, {Victor A.} and Anjana Kalita and Alfredo Torres",
year = "2013",
doi = "10.1016/j.vaccine.2013.05.013",
language = "English (US)",
volume = "31",
pages = "3229--3235",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "32",

}

TY - JOUR

T1 - Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection

AU - Garcia-Angulo, Victor A.

AU - Kalita, Anjana

AU - Torres, Alfredo

PY - 2013

Y1 - 2013

N2 - Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective clinical treatment, sequelae after infection and mortality rate in humans supports the urgent need of prophylactic approaches, such as development of vaccines. Shedding from cattle, the main EHEC reservoir and considered the principal food contamination source, has prompted the development of licensed vaccines that reduce EHEC colonization in ruminants. Although murine models do not fully recapitulate human infection, they are commonly used to evaluate EHEC vaccines and the immune/protective responses elicited in the host. Mice susceptibility differs depending of the EHEC inoculums; displaying different mortality rates and Stx-mediated renal damage. Therefore, several experimental protocols have being pursued in this model to develop EHEC-specific vaccines. Recent candidate vaccines evaluated include those composed of virulence factors alone or as fused-subunits, DNA-based, attenuated bacteria and bacterial ghosts. In this review, we summarize progress in the design and testing of EHEC vaccines and the use of different strategies for the evaluation of novel EHEC vaccines in the murine model.

AB - Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective clinical treatment, sequelae after infection and mortality rate in humans supports the urgent need of prophylactic approaches, such as development of vaccines. Shedding from cattle, the main EHEC reservoir and considered the principal food contamination source, has prompted the development of licensed vaccines that reduce EHEC colonization in ruminants. Although murine models do not fully recapitulate human infection, they are commonly used to evaluate EHEC vaccines and the immune/protective responses elicited in the host. Mice susceptibility differs depending of the EHEC inoculums; displaying different mortality rates and Stx-mediated renal damage. Therefore, several experimental protocols have being pursued in this model to develop EHEC-specific vaccines. Recent candidate vaccines evaluated include those composed of virulence factors alone or as fused-subunits, DNA-based, attenuated bacteria and bacterial ghosts. In this review, we summarize progress in the design and testing of EHEC vaccines and the use of different strategies for the evaluation of novel EHEC vaccines in the murine model.

KW - Bacterial ghost

KW - Diarrhea

KW - EHEC

KW - Enterohemorrhagic E. coli

KW - Murine model

KW - Shiga toxin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84879463772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879463772&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.05.013

DO - 10.1016/j.vaccine.2013.05.013

M3 - Article

C2 - 23707170

AN - SCOPUS:84879463772

VL - 31

SP - 3229

EP - 3235

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 32

ER -